 Home > Active Ingredient News > Drugs Articles > Yinming Biotechnology completes nearly US$50 million in A+ round of financing

Yinming Biotechnology completes nearly US$50 million in A+ round of financing

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

bacteria battling drug

alimta drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 13, Guangzhou Yinming Biomedical Technology Co.
, Ltd.
(MingMed, hereinafter referred to as "Yinming Bio") announced that the company has completed nearly US$50 million in A+ round of financing
.

In this round of financing, the original investors of Yinming Biotech, Gaorong Capital, Jingcheng Capital, and Huacheng Venture Capital continue to add additional investment, and the new investment of Fangjifeng Capital, Yixian E-commerce, Haisong Capital, Efeng Capital, Taixin Capital, etc.

The company has completed nearly 50 million U.

Public information shows that Yinming was established in October 2019 and is committed to the research and development of "first-in-class" new drugs.
The company's co-founder and CEO (CEO) is Mr.
Zhang Yan
.

In March 2021, the company just announced the completion of a US$60 million Series A financing led by Gaorong Capital

The company's co-founder and chief executive officer (CEO) is Mr.

Regarding this round of financing, Mr.
Zhang Yan, co-founder and CEO (CEO) of Yinming Biotech, introduced: " In the past six months, Yinming Biotech has completed two consecutive rounds of financing, with a cumulative financing amount of nearly 110 million U.
S.
dollars
.

We.

In the past 6 months, Yinming has completed two consecutive rounds of financing, with a cumulative financing amount of nearly US$110 million.

Reference materials:

[1]Yinming has completed nearly US$50 million in Series A+ financing to accelerate clinical trials of blockbuster pipeline drug candidates.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.